If you are considering the GeneSight pharmacogenomic test to guide your mental health treatment, the decision is no longer just about the science; it is about navigating a complex 2026 landscape of ...
Myriad Genetics, Inc. MYGN recently announced improvements to the GeneSight Psychotropic test, a pharmacogenomic test for drugs used to treat mental illness. The GeneSight report will now contain ...
Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that ...
Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...
The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...
video: A new GeneSight Mental Health Monitor national survey finds 83 percent of those diagnosed with depression say life would be easier if others could understand what they're going through. Yet, ...
New study finds GeneSight CPGx precision medicine test provides significant health care cost savings
Mason, Ohio - August 12, 2015 - A new study published in Current Medical Research and Opinion demonstrated $1,036 in annual prescription savings per patient when healthcare providers used the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results